Zaburzenia metabolizmu lekow zwiazane z interakcjami pomiedzy zywnoscia a lekami

• Autorzy: Jarosz M

Warianty tytułu

EN

Drug metabolism disturbances related to food and drug interactions

• Języki publikacji: PL

Słowa kluczowe

PL

zywnosc; zaburzenia metabolizmu; pacjenci; interakcje lekowe; konferencje; leczenie; leki; zywienie czlowieka; Warszawa konferencja

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm. Suplement
• Rocznik: 2004
• Tom: 31
• Numer: 2 cz.1
• Opis fizyczny: s.162-169,tab.,bibliogr.

Twórcy

autor

Jarosz M

• Instytut Zywnosci i Zywienia, Warszawa

Bibliografia

• 1. Ameer B., Weintraub R.A.: Drug interactions with grapefruit juice. Clin Pharmacokinet., 1997, 33, 103-121.
• 2. Bailey D.G., Arnold J.M.O., Munoz C., Spence J.D.: Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin. Pharmacol. Ther., 1993, 53, 637-642.
• 3. Bailey D.G., Arnold J.M.O., Strong H.A., et al.: Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin. Pharmacol. Ther., 1993, 54, 589-594.
• 4. Bailey D.G., Malcolm J., Arnold O., Spence J.D.: Grapefruit juice - drug interactions. Br. J. Clin. Pharmacol., 1998, 46, 101-110.
• 5. Bailey D.G., Spence J.D., Munoz C., Arnold J.M.O.: Interactions of citrus juices with felodipine and nifedipine. Lancet 1991, 337, 268- 269.
• 6. Baldessarini R.J.: Drugs and the treatment of psychiatric disorders. In: Goodman and Gilman’s the pharmacological basis of therapeutics, 8th ed. Gilman A., et al. eds., New York, Pergamon, 1990, p. 417.
• 7. Benton R.E., Honing P.K., Zamani K., et al.: Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin. Pharmacol. Ther., 1996, 59, 383-388.
• 8. Bertz R.J., Granneman G.R.: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet., 1997, 32, 210-218.
• 9. Blackwell B.: Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet, 1963, 11, 849-851.
• 10. Bland S.E.: Drug-food interactions. J. Pharm. Soc. Wiscon., 1998, 6, 28-35.
• 11. Brown C., et al.: The monoamine oxidase inhibitor - tyramine interaction. J. Clin. Pharmacol., 1989, 29, 529-532.
• 12. Charman W.N., Porter C.J., Mithani S., Dressman J.B.: Physiochemical and physiological mechanisms for the effects of food on drug absorbtion: the role of lipids and pH. J. Pharm. Sci., 1997, 86, 269-282.
• 13. Cook C.S., Zhang L., Osis J., et al.: Mechanisms of compound - and species - specific food effects of structurally related antiarrhythmic drugs, disopyramide and bidisomide. Pharm. Res., 1998, 15, 429-433.
• 14. Ducharme M.P., Provenzano R., Dehoorne-Smith M., Edwards D.J.: Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br. J. Clin. Pharmacol., 1993, 36, 457-459.
• 15. Edgar B., et al.: Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine - and its potential clinical relevance. Eur. J. Clin. Pharmacol., 1992, 42, 313-317.
• 16. Folks D.G.: Monoamine oxidase inhibitors: Reappraisal of dietary considerations. J. Clin. Psychopharmacol., 1983, 3, 249- 252.
• 17. Fuhr U., et al.: Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br. J. Clin. Pharmacol., 1993, 35, 431-436.
• 18. Fuhr U., Maier Brüggemann A., Blume H., et al.: Grapefruit juice increases oral nimodipine bioavailability. Int. J. Clin. Pharmacol. Ther., 1998, 36, 126-132.
• 19. Fuhr U.: Drug interactions with grapefruit juice. Extent, propable mechanism and clinical relevance. Drug Safe 1998, 18, 251- 272.
• 20. Generali J.A., et al.: Hypertensive crisis resulting from avocados and MAO inhibitor. Drug. Intell. Clin. Pharm., 1981, 15, 904-906.
• 21. Gertig H.: Interakcje leków z żywnością. Żywienie człowieka zdrowego i chorego. Red.: J. Hasik, J. Gawęcki. Warszawa, PWN, 317-325.
• 22. Graedon J., Graedon T.: The people guide to deadly drug interactions. Graedon Enterprises, Inc. St.Martin’s Press, New York, 1995.
• 23. Guengerich F.P., Kim D.H.: In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogen 1992, 11, 2275-2279.
• 24. Hedberg D.L., et al.: Six cases of hypertensive crisis in patients on tranylcypromine after eating chicken livers. Am. J. Psychiatry, 1966, 122, 933-937.
• 25. Hukkinen S.K., Varhe A., Olkkola K.T., Neuvonen P.J.: Plasma concentrations of triacolam are increased by concomitant ingestion of grapefruit juice. Clin. Pharmacol. Ther., 1995, 58, 127-131. 26. Jarosz M., Dzieniszewski J.: Interakcje pomiędzy lekami a żywnością. Warszawa, MI Polska, 2000.
• 27. Kantola T., Kivistö K.T., Nevvonen P.J.: Grapefruit juice greatly increases serum concentrations of Lovastatin an lovastatin acid. Clin. Pharmacol. Ther., 1998, 63, 397-402.
• 28. Kappus A., et al.: Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clin. Pharmacol. Ther., 1978, 23, 445-449.
• 29. Kivistö K.T., Bookjans G., Fromm M.F., et al: Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br. J. Clin. Pharmacol., 1996, 42, 387-389.
• 30. Kolars J.C., Lown K.S., Schmiedlin-Ren P., et al.: CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994, 4, 247-259.
• 31. Kostowski W., Kubikowski: Farmakologia, podstawy farmakoterapii i farmakologii klinicznej. Warszawa, PZWL, 1997.
• 32. Kupferschmidt H.H.T., Ha H.R., Ziegler W.H., et al.: Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther., 1995, 58, 20-28.
• 33. Lea A.P., McTavish D.: Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997, 53, 828-847.
• 34. Lennernäs H., Fager G.: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin. Pharmacokinet., 1997, 32, 403-425.
• 35. Liedholm H., Lidin A.: Food intake and the presystemic metabolism of single dose of amitriptyline and nortrptyline. Fundam. Clin. Pharmacol., 1998, 12, 636-642.
• 36. McCabe B.L.: Dietary tyramine and other pressor amines in MAOI regimens: a review. J. Am. Diet. Assoc., 1986, 86, 1059- 1064.
• 37. Netzer P., Eschenmoser K., Halter F., Inauen W.: Impact of food intake on the antisecretory effect of low-dose ranitidine and famotidine. Aliment. Pharmacol. Ther., 1999, 13, 407-412.
• 38. Neuvonen P.J., Kantola T., Kivistö K.T.: Simvastatin but not pravstatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther., 1998, 63, 332-341.
• 39. Roe D.A.: Diet, nutrition and drug reactions. In: Modern nutrition in health and disease, 7th ed. M.E. Shils and V.R. Young, eds. Philadelphia: Lea and Febiger, 1988, 630-645.
• 40. Self T.H., Chrisman C.R., Baciewicz A.M., Bronze M.S.: Isoniazid drug and food interactions. Am. J. Med. Sci., 1999, 317, 304-311.
• 41. Stewart D.E.: High-fiber diet and serum tricyclic antidepressant levels. J. Clin. Psychopharmacol., 1992, 12, 438-440.
• 42. WHO Drug Information, Geneve, 1998, 12, 1.1. Ameer B., Weintraub R.A.: Drug interactions with grapefruit juice. Clin Pharmacokinet., 1997, 33, 103-121.
• 2. Bailey D.G., Arnold J.M.O., Munoz C., Spence J.D.: Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin. Pharmacol. Ther., 1993, 53, 637-642.
• 3. Bailey D.G., Arnold J.M.O., Strong H.A., et al.: Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin. Pharmacol. Ther., 1993, 54, 589-594.
• 4. Bailey D.G., Malcolm J., Arnold O., Spence J.D.: Grapefruit juice - drug interactions. Br. J. Clin. Pharmacol., 1998, 46, 101-110.
• 5. Bailey D.G., Spence J.D., Munoz C., Arnold J.M.O.: Interactions of citrus juices with felodipine and nifedipine. Lancet 1991, 337, 268- 269.
• 6. Baldessarini R.J.: Drugs and the treatment of psychiatric disorders. In: Goodman and Gilman’s the pharmacological basis of therapeutics, 8th ed. Gilman A., et al. eds., New York, Pergamon, 1990, p. 417.
• 7. Benton R.E., Honing P.K., Zamani K., et al.: Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin. Pharmacol. Ther., 1996, 59, 383-388.
• 8. Bertz R.J., Granneman G.R.: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet., 1997, 32, 210-218.
• 9. Blackwell B.: Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet, 1963, 11, 849-851.
• 10. Bland S.E.: Drug-food interactions. J. Pharm. Soc. Wiscon., 1998, 6, 28-35.
• 11. Brown C., et al.: The monoamine oxidase inhibitor - tyramine interaction. J. Clin. Pharmacol., 1989, 29, 529-532.
• 12. Charman W.N., Porter C.J., Mithani S., Dressman J.B.: Physiochemical and physiological mechanisms for the effects of food on drug absorbtion: the role of lipids and pH. J. Pharm. Sci., 1997, 86, 269-282.
• 13. Cook C.S., Zhang L., Osis J., et al.: Mechanisms of compound - and species - specific food effects of structurally related antiarrhythmic drugs, disopyramide and bidisomide. Pharm. Res., 1998, 15, 429-433.
• 14. Ducharme M.P., Provenzano R., Dehoorne-Smith M., Edwards D.J.: Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br. J. Clin. Pharmacol., 1993, 36, 457-459.
• 15. Edgar B., et al.: Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine - and its potential clinical relevance. Eur. J. Clin. Pharmacol., 1992, 42, 313-317.
• 16. Folks D.G.: Monoamine oxidase inhibitors: Reappraisal of dietary considerations. J. Clin. Psychopharmacol., 1983, 3, 249- 252.
• 17. Fuhr U., et al.: Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br. J. Clin. Pharmacol., 1993, 35, 431-436.
• 18. Fuhr U., Maier Brüggemann A., Blume H., et al.: Grapefruit juice increases oral nimodipine bioavailability. Int. J. Clin. Pharmacol. Ther., 1998, 36, 126-132.
• 19. Fuhr U.: Drug interactions with grapefruit juice. Extent, propable mechanism and clinical relevance. Drug Safe 1998, 18, 251- 272.
• 20. Generali J.A., et al.: Hypertensive crisis resulting from avocados and MAO inhibitor. Drug. Intell. Clin. Pharm., 1981, 15, 904-906.
• 21. Gertig H.: Interakcje leków z żywnością. Żywienie człowieka zdrowego i chorego. Red.: J. Hasik, J. Gawęcki. Warszawa, PWN, 317-325.
• 22. Graedon J., Graedon T.: The people guide to deadly drug interactions. Graedon Enterprises, Inc. St.Martin’s Press, New York, 1995.
• 23. Guengerich F.P., Kim D.H.: In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogen 1992, 11, 2275-2279.
• 24. Hedberg D.L., et al.: Six cases of hypertensive crisis in patients on tranylcypromine after eating chicken livers. Am. J. Psychiatry, 1966, 122, 933-937.
• 25. Hukkinen S.K., Varhe A., Olkkola K.T., Neuvonen P.J.: Plasma concentrations of triacolam are increased by concomitant ingestion of grapefruit juice. Clin. Pharmacol. Ther., 1995, 58, 127-131. 26. Jarosz M., Dzieniszewski J.: Interakcje pomiędzy lekami a żywnością. Warszawa, MI Polska, 2000.
• 27. Kantola T., Kivistö K.T., Nevvonen P.J.: Grapefruit juice greatly increases serum concentrations of Lovastatin an lovastatin acid. Clin. Pharmacol. Ther., 1998, 63, 397-402.
• 28. Kappus A., et al.: Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clin. Pharmacol. Ther., 1978, 23, 445-449.
• 29. Kivistö K.T., Bookjans G., Fromm M.F., et al: Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br. J. Clin. Pharmacol., 1996, 42, 387-389.
• 30. Kolars J.C., Lown K.S., Schmiedlin-Ren P., et al.: CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994, 4, 247-259.
• 31. Kostowski W., Kubikowski: Farmakologia, podstawy farmakoterapii i farmakologii klinicznej. Warszawa, PZWL, 1997.
• 32. Kupferschmidt H.H.T., Ha H.R., Ziegler W.H., et al.: Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther., 1995, 58, 20-28.
• 33. Lea A.P., McTavish D.: Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997, 53, 828-847.
• 34. Lennernäs H., Fager G.: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin. Pharmacokinet., 1997, 32, 403-425.
• 35. Liedholm H., Lidin A.: Food intake and the presystemic metabolism of single dose of amitriptyline and nortrptyline. Fundam. Clin. Pharmacol., 1998, 12, 636-642.
• 36. McCabe B.L.: Dietary tyramine and other pressor amines in MAOI regimens: a review. J. Am. Diet. Assoc., 1986, 86, 1059- 1064.
• 37. Netzer P., Eschenmoser K., Halter F., Inauen W.: Impact of food intake on the antisecretory effect of low-dose ranitidine and famotidine. Aliment. Pharmacol. Ther., 1999, 13, 407-412.
• 38. Neuvonen P.J., Kantola T., Kivistö K.T.: Simvastatin but not pravstatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther., 1998, 63, 332-341.
• 39. Roe D.A.: Diet, nutrition and drug reactions. In: Modern nutrition in health and disease, 7th ed. M.E. Shils and V.R. Young, eds. Philadelphia: Lea and Febiger, 1988, 630-645.
• 40. Self T.H., Chrisman C.R., Baciewicz A.M., Bronze M.S.: Isoniazid drug and food interactions. Am. J. Med. Sci., 1999, 317, 304-311.
• 41. Stewart D.E.: High-fiber diet and serum tricyclic antidepressant levels. J. Clin. Psychopharmacol., 1992, 12, 438-440.
• 42. WHO Drug Information, Geneve, 1998, 12, 1.